Andrew Hopkins is the founder and CEO of Exscientia Ltd. Exscientia is the first company to automate drug design, using A.I., surpassing conventional human endeavors. Andrew is the author of some of the most highly cited papers in modern drug discovery. Prof Hopkins spent ten years at the Pfizer, following his DPhil at the University of Oxford. Subsequently, he was one of the youngest professors when he was appointed to a Chair at the University of Dundee. Prof Hopkins has raised around £50 million for commercial and academic research activities. He has won several awards for his work including the Royal Society of Chemistry’s Entrepreneur of the Year and the Capps Green Zomaya Medal, the BBSRC Commercial Innovator of the Year, Scottish Enterprise Life Science Entrepreneurial Leadership Award, and the Corwin Hansch Award. Andrew is a Fellow of the RSE, the RSC, the RSB and the LSW. Prof Hopkins lives in Oxford, UK.
Andrew spent 10 years at Pfizer, where he was responsible for establishing new research foci including the concepts of druggability and network pharmacology. Andrew has raised a total of $50 million for academic and commercial research activities in his continuing role as Chair of Medicinal Informatics at the University of Dundee. He is the author of some of the most highly cited papers in modern drug discovery